Guidelines for laboratory monitoring of treatment of persistent virus infections.
A growing number of antiviral agents are available for treatment of persistent viral infections. This has increased the requirement for virology laboratories to undertake sophisticated assays for monitoring the efficacy of treatment and identifying drug failure at an early stage. The consensus guidelines within this article address the laboratory requirements for monitoring treatment of the herpes viruses, HIV-1, Hepatitis B and Hepatitis C.
PHLS Antiviral Susceptibility Reference Unit, Department of Immunity and Infection, University of Birmingham Medical School, Edgbaston, B15 2TT, Birmingham, UK
D
D
Pillay
V C
VC
Emery
D
D
Mutimer
M M
MM
Ogilvie
W
W
Carman
K
K
Mutton
T
T
Wreghitt
D
D
Westmoreland
J
J
Breuer
M
M
Zuckerman
D002644:Chickenpox / Q000188:drug therapy / Q000821:virology; D019411:Clinical Laboratory Techniques / Q000592:standards*; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000821:virology; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D015497:HIV-1; D006509:Hepatitis B / Q000188:drug therapy / Q000821:virology; D006526:Hepatitis C / Q000188:drug therapy / Q000821:virology; D006561:Herpes Simplex / Q000188:drug therapy / Q000821:virology; D006801:Humans; D007753:Laboratories; D007755:Laboratories, Hospital / Q000592:standards*; D017056:Medical Laboratory Personnel; D017410:Practice Guidelines as Topic; D014777:Virus Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000821:virology; D017735:Virus Latency